1. Home
  2. WOW vs DMAC Comparison

WOW vs DMAC Comparison

Compare WOW & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo WideOpenWest Inc.

WOW

WideOpenWest Inc.

HOLD

Current Price

$5.20

Market Cap

446.5M

ML Signal

HOLD

Logo DiaMedica Therapeutics Inc.

DMAC

DiaMedica Therapeutics Inc.

HOLD

Current Price

$7.87

Market Cap

428.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WOW
DMAC
Founded
2001
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Cable & Other Pay Television Services
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
446.5M
428.6M
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
WOW
DMAC
Price
$5.20
$7.87
Analyst Decision
Hold
Strong Buy
Analyst Count
2
4
Target Price
$5.20
$15.50
AVG Volume (30 Days)
556.6K
442.9K
Earning Date
11-05-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$590,800,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.06
$3.19
52 Week High
$5.33
$10.42

Technical Indicators

Market Signals
Indicator
WOW
DMAC
Relative Strength Index (RSI) 54.87 44.35
Support Level $5.16 $8.16
Resistance Level $5.23 $8.45
Average True Range (ATR) 0.02 0.50
MACD 0.00 -0.15
Stochastic Oscillator 57.14 6.03

Price Performance

Historical Comparison
WOW
DMAC

About WOW WideOpenWest Inc.

WideOpenWest Inc is a cable operator and broadband service, provider. The company serves residential, business and wholesale customers in Illinois, Michigan, Indiana, Ohio, Kansas, Tennessee, Maryland, and South Carolina. Its service portfolio consists of high-speed internet, data, voice, cloud, and cable television services. The company operates in one business segment that is Broadband Services. The majority of the revenue is generated from the subscription service revenue received.

About DMAC DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

Share on Social Networks: